Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation
The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The main objective of this study was to evaluate comparative biodistribution and pharmacokinetics of cyclosporine-A (CsA) following intranasal (IN) administration versus intravenous (IV) administration in Sprague-Dawley rats using an oil-in-water nanoemulsion delivery system. CsA, a hydrophobic peptide that is also a substrate for P-glycoprotein, is a well-known immunosuppressive agent. In the brain, CsA has been shown to be a potent anti-inflammatory and neuroprotective agent. CsA nanoemulsions (CsA-NE) and solution formulations (CsA-S) were prepared using an ultrasonication method and were characterized for drug content, encapsulation efficiency, globule size, and zeta potential. We compared the uptake of CsA-NE and CsA-S in brain regions and peripheral organs following IN and IV administration using LC-MS/MS based bioanalytical method. CsA-NE IN resulted in the highest accumulation compared to that with any other treatment and route of administration; this was consistent for all three regions of brain that were evaluated (olfactory bulbs, mid brain, and hind brain). The brain/blood exposure ratios of 4.49, 0.01, 0.33, and 0.03 for CsA-NE (IN), CsA-NE (IV), CsA-S (IN), and CsA-S (IV), respectively, indicated that CsA-NE is capable of direct nose-to-brain transport, bypassing the blood-brain barrier. Furthermore, CsA-NE administration reduces nontarget organ exposure. These studies show that IN delivery of CsA-NE is an effective way of brain targeting compared to that of other treatment strategies. This approach not only enhances the brain concentration of the peptide but also significantly limits peripheral exposure and the potential for off-target toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study demonstrated that cyclosporine-A is not efficiently transported into the brain through the BBB upon intravenous administration, while nasal administration of cyclosporine-A loaded NEs is an effective way of brain targeting.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [61]
In the citing paper
“This study demonstrated that cyclosporine-A is not efficiently transported into the brain through the BBB upon intravenous administration, while nasal administration of cyclosporine-A loaded NEs is an effective way of brain targeting.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [61]
In the citing paper
“The nasal administration of NEs enhances the brain concentration of cyclosporine-A and significantly limits its peripheral exposure and toxicity.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [61]
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Physiology of the CSF and Blood-Brain Barriers
Davson, H., & Segal, M. B. (1996) · Medical Entomology and Zoology · Cited by 582
Quantitative analysis of the olfactory pathway for drug delivery to the brain
Thorne, R. G., Emory, C. R., Ala, T. A., & Frey, W. H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00637-6 · Cited by 352
Vyas, T. K., Shahiwala, A., & Amiji, M. M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.016 · Cited by 264
Self-citationBradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors
Inamura, T., & Black, K. L. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.108 · Cited by 160
Research works printed but not linked: 2
- Guan P., 2011, Int. J. Nanomed., 6, 965
- Andersson J., 1992, Immunology, 75, 136
Cited by
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
“These observations indicated that CsA-NE was capable of directing nose-to-brain transport without systemic absorption [206].”
BackgroundNanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
“compared pharmacokinetics and bioavailability studies of NEs containing cyclosporine-A when administered by nasal and intravenous routes in Sprague−Dawley rats [61].”
ResultJeong, S.-H., Jang, J.-H., & Lee, Y.-B. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00589-5 · Cited by 256
Chatterjee, B., Gorain, B., Mohananaidu, K., Sengupta, P., Mandal, U. K., & Choudhury, H. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.032 · Cited by 216
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 178
Koo, J., Lim, C., & Oh, K. T. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439181 · Cited by 174
“63,156 This observation holds significance in the context of diseases that frequently manifest in the forebrain, such as glioblastoma, suggesting the potential effectiveness of intranasal administration for therapeutic intervention.”
BackgroundIntranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 170
“Furthermore, the intranasal NE reduced the nontarget organ exposure [55].”
BackgroundIntranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes
Dhaliwal, H. K., Fan, Y., Kim, J., & Amiji, M. M. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00170 · Cited by 136
Self-citationAn update on the role of nanovehicles in nose-to-brain drug delivery
Feng, Y., He, H., Li, F., Lü, Y., Qi, J., & Wu, W. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.005 · Cited by 135
Kumar, S., Ali, J., & Baboota, S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/43/435101 · Cited by 115
Akel, H., Ismail, R., & Csóka, I. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.12.014 · Cited by 107
Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges
Karami, Z., Zanjani, M. R. S., & Hamidi, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.021 · Cited by 108
Treatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach
Kaur, A., Nigam, K., Bhatnagar, I., Sukhpal, H., Awasthy, S., Shankar, S., Tyagi, A. K., & Dang, S. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00754-z · Cited by 106
Nanoparticle-Based Drugs and Formulations: Current Status and Emerging Applications
Kumar, R., Dalvi, S. V., & Siril, P. F. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c00606 · Cited by 110
Nasal Drug Delivery Systems: An Overview
Ghori, M. U., Mahdi, M. H., Smith, A. M., & Conway, B. R. (2015) · University of Huddersfield Repository (University of Huddersfield) · doi:10.12691/ajps-3-5-2 · Cited by 82
Nano-enabled delivery of diverse payloads across complex biological barriers
Ross, K. A., Brenza, T. M., Binnebose, A. M., Phanse, Y., Kanthasamy, A. G., Gendelman, H. E., Salem, A. K., Bartholomay, L. C., Bellaire, B. H., & Narasimhan, B. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.039 · Cited by 74
Borrajo, M. L., & Alonso, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01086-2 · Cited by 78
Patharapankal, E. J., Ajiboye, A. L., Mattern, C., & Trivedi, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010066 · Cited by 82
Elezaby, R. S., Gad, H. A., Metwally, A. A., Geneidi, A. S., & Awad, G. A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.019 · Cited by 60
Direct nose to the brain nanomedicine delivery presents a formidable challenge
Yokel, R. A. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1767 · Cited by 65
Bose, M., Quipildor, G. F., Ehrlich, M. E., & Salton, S. R. (2022) · Cells · doi:10.3390/cells11223629 · Cited by 49
Michels, L. R., Fachel, F. N. S., Schuh, R. S., Azambuja, J. H., de Souza, P. O., Gelsleichter, N. E., Lenz, G. S., Visioli, F., Braganhol, E., & Teixeira, H. F. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.070 · Cited by 48
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 47
Kamei, N., Suwabe, S., Arime, K., Bando, H., Murata, K., Yamaguchi, M., Yokoyama, N., Tanaka, E., Hashimoto, A., Kanazawa, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111745 · Cited by 38
Ghosh, A., Majie, A., Karmakar, V., Chatterjee, K., Chakraborty, S., Pandey, M., Jain, N., Sarkar, S. R., Nair, A. B., & Gorain, B. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02810-0 · Cited by 41
Nanoparticle Brain Delivery: A Guide to Verification Methods
Yokel, R. A. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0169 · Cited by 42
“…by LC–MS / MS after intranasal dosing of 272-nm nanoemulsion to the rat LC–MS / MS NP component shows bulk brain distribution; 1 2.4 and 2.6 [122] ‘NPs were capable of penetrating cell membranes and entering cellular compartments’ Brains from mice with green fluorescent protein-expressing…”
BackgroundInfluentialNanoparticle delivery systems for substance use disorder
Kasina, V., Mownn, R. J., Bahal, R., & Sartor, G. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01311-7 · Cited by 39
“Secondly, what is the best route of delivery? In preclinical studies, intranasal delivery of drugbound nanoparticles showed superior pharmacokinetic qualities and CNS bioavailability when directly compared to intravenous delivery [162].”
BackgroundHefnawy, A., Khalil, I. A. H., & El-sherbiny, I. M. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0243 · Cited by 35
El-Setouhy, D. A., Ibrahim, A. B., Amin, M. M., Khowessah, O. M., & Elzanfaly, E. S. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.002 · Cited by 35
El‐Safoury, D. M., Ibrahim, A. B., El-Setouhy, D., Khowessah, O. M., Motaleb, M., & Sakr, T. M. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.021 · Cited by 32
Shobo, A., Pamreddy, A., Kruger, H. G., Makatini, M. M., Naicker, T., Govender, T., & Baijnath, S. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0365 · Cited by 23
Alexander, A., Agrawal, M., Chougule, M. B., Saraf, S., & Saraf, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817778-5.00009-9 · Cited by 37
Non-Invasive Techniques of Nose to Brain Delivery Using Nanoparticulate Carriers: Hopes and Hurdles
Butola, M., & Nainwal, N. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02946-z · Cited by 38
“…brain/blood exposure ratio, of 4.49, 0.01, 0.33, and 0.03 CS-A-NE may cross the blood–brain barrier and directly pass from the nose to the brain [152] Tramadol Isopropyl myristate 136.3 nm The results of accelerated stability testing indicated that both the tramadol microemulsion (TME) and…”
InfluentialWu, D., Salah, Y. A., Ngowi, E. E., Zhang, Y., Khattak, S., Khan, N. H., Wang, Y., Li, T., Guo, Z.-H., Wang, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107321 · Cited by 35
“The brain/blood exposure ratios indicated that CsA-NE can bypass the bloodbrain barrier through a direct nose-to-brain pathway mitigating untargeted tissue exposure.(97)”
BackgroundAdvanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides
Lin, J., Yu, Z., & Gao, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c06851 · Cited by 32
The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies
Zhang, H., Wu, A., Nan, X., Yang, L., Zhang, D., Zhang, Z., & Liu, H. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00325 · Cited by 27
Gao, W., Yang, X., Lin, Z., He, B., Mei, D., Wang, D., Zhang, H., Zhang, H., Dai, W., Wang, X., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.018 · Cited by 23
Yadav, S. K., Pawar, G. N., Kulkarni, P. P., Ferris, C. F., & Amiji, M. M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254672 · Cited by 23
“The better effect observed with a nanoemulsion again highlights the importance of using nanoemulsions, which have shown better brain-targeting efficiency based on the distribution study performed earlier (Yadav et al., 2015).”
BackgroundSelf-citationKadakia, E., Bottino, D. C., & Amiji, M. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2610-y · Cited by 20
Self-citationSchlachet, I., Halamish, H. M., & Sosnik, A. (2020) · Molecules · doi:10.3390/molecules25194496 · Cited by 22
“: (i) there was higher accumulation in the brain [51] and (ii) the accumulation was less spread, enabling targeting of the nanoparticles to more specific CNS regions, which is associated with the nanoparticle properties [56] and probably with the type of nasal nanoformulation [54].”
BackgroundIntranasal lipid nanocarriers: Uptake studies with fluorescently labeled formulations
Muntoni, E., Marini, E., Ferraris, C., Garelli, S., Capucchio, M. T., Colombino, E., Panciani, P. P., & Battaglia, L. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112470 · Cited by 19
“Recently, animal studies have shown that nanoemulsions effectively promoted nasal delivery of small molecular weight hydrophobic molecules, such as cyclosporine-A, to the brain without systemic absorption [49].”
El‐Safoury, D. M., Ibrahim, A. B., El-Setouhy, D. A., Khowessah, O. M., Motaleb, M. A., & Sakr, T. M. (2021) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-021-07633-y · Cited by 15
Intranasal delivery of metformin using metal–organic framework (MOF)-74-Mg nanocarriers
Yuan, M., Han, Z., Somayaji, Y., Nguyen, N., Hu, H., Madhu, L. N., Attaluri, S., Kodali, M., Yang, Y., Hsu, Y., et al. (2025) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-025-01227-y · Cited by 16
Maaz, A., Blagbrough, I. S., & Bank, P. D. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00639 · Cited by 14
Tomar, S., Yadav, R. K., Shah, K., & Dewangan, H. K. (2022) · International Journal of Polymeric Materials · doi:10.1080/00914037.2022.2124255 · Cited by 18
“These findings suggested that CsA-NE might control nose-to-brain transport without causing systemic absorption [77] .”
BackgroundIntranasal delivery of iron chelators and management of central nervous system disease
Cheng, R., & Kim, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1709259 · Cited by 15
Sabir, F., Ain, Q. U., Rahdar, A., Yang, Z., Barani, M., Bilal, M., & Bhalla, N. (2022) · Springer eBooks · doi:10.1007/978-981-16-6819-7_21 · Cited by 13
Nose-to-brain delivery of biologics and stem cells
Agrawal, M., Konwar, A. N., Alexander, A., & Borse, V. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00015-1 · Cited by 9
Delivery of gene editing therapeutics
Kevadiya, B. D., Islam, F. S., Deol, P., Zaman, L. A., Mosselhy, D. A., Ashaduzzaman, M., Bajwa, N., Routhu, N. K., Singh, P. A., Dawre, S., et al. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102711 · Cited by 14
Kadakia, E., Harpude, P., Parayath, N. N., Bottino, D. C., & Amiji, M. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2667-7 · Cited by 10
Self-citationHyun, S., Park, N., Nam, S. H., Cheon, D. H., Lee, Y., Lim, H., & Yu, J. (2021) · Chemical Communications · doi:10.1039/d0cc08268f · Cited by 10
Overcoming barriers: nanomedicine-based strategies for nose-to-brain delivery
Paraiso, W. K. D., Ramos, C. P., Hossain, P. M., Gordi, C. A., Guillen-Poza, P. A., Zagmutt, S., Quader, S., & Rodríguez‐Rodríguez, R. (2025) · Nanoscale · doi:10.1039/d5nr02259b · Cited by 10
Challenges in Targeting Nasal Passage and Nose-to-Brain Delivery via Nanoemulsions
Bahadur, S., & Pathak, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-23112-4_5 · Cited by 7
Intranasal delivery systems for traumatic brain injury: Advancements and perspectives
Yoo, S. H., Heo, S. C., Bae, J. S., Lee, J. H., Knowles, J. C., & Kim, H. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314251372373 · Cited by 7
Chemically conjugated novel liposomal formulation for intravenous delivery of cyclosporin A
Park, Y., Min, K. A., Song, Y., Ham, S., & Kim, C. (2016) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2016.02.008 · Cited by 5
Teklezgi, B. G., Pamreddy, A., Ntshangase, S., Mdanda, S., Singh, S. D., Gopal, N. D., Naicker, T., Kruger, H. G., Govender, T., & Baijnath, S. (2020) · ACS Omega · doi:10.1021/acsomega.9b03570 · Cited by 5
Intranasal route: The green corridor for Alzheimer's disease therapeutics
Chaudhury, S. S., Sinha, K., & Mukhopadhyay, C. D. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102791 · Cited by 5
Strategies for enhanced direct nose-to-brain drug delivery
Madav, Y., & Wairkar, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00014-x · Cited by 4
Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination
Müller-Goymann, C. C., & Paranjpe, M. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch26 · Cited by 4
Containers for Encapsulation of Fragrances/Aroma/Odour for Textile Applications
Bhatt, L., Kholiya, R., & Tewari, S. (2022) · Composites science and technology · doi:10.1007/978-981-16-8146-2_7 · Cited by 3
Cyclosporine A Loaded Nanoemulsions using Bio-oil Fractions of Sesame Oil
Bhargava, S., & Madhav, N. S. (2020) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.54.2.41 · Cited by 2
Kotha, A. K., Ghosh, S., Komanduri, N., Wang, R., Bhowmick, S., & Chougule, M. B. (2019) · Springer eBooks · doi:10.1007/978-981-13-3642-3_11 · Cited by 4
NOSE-TO-BRAIN DELIVERY, A ROUTE OF CHOICE FOR TARGETING BRAIN TUMORS
Shehu, I. A., ISLAM, M., & Singh, V. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i3.40602 · Cited by 2
“It was identified to have reached the brain through the olfactory bulb, hindbrain, and midbrain (via olfactory epithelium) through CSF [56].”
BackgroundInfluentialParticulate carriers for nose-to-brain delivery
Bahadur, S., & Pathak, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00009-6 · Cited by 2
NOVEL DRUG DELIVERY SYSTEM THROUGH NASAL (NON-INVASIVE)
Ramachandran, S. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11s4.31705 · Cited by 1
Seyhan, V., Özdemir, S., Demirkoz, A. B., & Üner, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_301-1 · Cited by 1
Development of lipid- and polymer-based nanocarriers for intranasal application
Akel, H. (2022) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11343 · Cited by 4
Kadakia, E. (2018) · Digital Repository Service (Northeastern University) · doi:10.17760/d20316233
Advances in Nanocarrier-Based Delivery of Therapeutic Peptides
Mittal, S., Singh, V., & Dang, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_19
MEDICAL OR THERAPEUTICAL APPLICATIONS OF OIL‐IN‐WATER NANOSIZED EMULSIONS
Katari, O., & Shunmugaperumal, T. (2020) · Wiley eBooks · doi:10.1002/9781119585275.ch6
Önel, G. T., & Saygılı, N. (2022) · ChemistrySelect · doi:10.1002/slct.202201654
Kamei, N., & Takeda‐Morishita, M. (2022) · Wiley eBooks · doi:10.1002/9783527835997.ch19
Sharma, R., Monika, Tyagi, B., Gupta, D., Mazumder, R., & Mazumder, A. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249329586240924105624 · Cited by 1
Nanoemulsions: New Approaches in Cancer Therapy with Herbal Terpenes and Essential Oils
Seyhan, V., Özdemir, S., Demirkoz, A. B., & Üner, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_301
Nasal in-situ Transferosomes as a Platform Technology for Nose-to-Brain Drug Delivery
., D., Shripathy, D., Pinto, A., Kulal, S., & Shabaraya, A. (2026) · Galore International Journal of Health Sciences and Research · doi:10.52403/gijhsr.20260303
Metadata
- Authors
- Yadav, S., Gattacceca, F., Panicucci, R., & Amiji, M. M.
- Affiliations
- Northeastern University (US)
- Inserm (FR)
- Novartis Institute of Biomedical Research, Cambridge, Massachusetts 02142, United States
- Corresponding author
- Amiji, Mansoor M.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-03-31
- Volume
- 12
- Issue
- 5
- Pages
- 1523-1533
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2332814906
- Cited by
- 76
- References
- 33
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 6 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 2
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R21-NS066984)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- cyclosporine, intranasal drug delivery, brain targeting, oil-in-water nanoemulsions, pharmacokinetics, tissue distribution, blood-brain barrier bypass, nose-to-brain transport, P-glycoprotein substrate, encapsulation efficiency, neuroprotection
- MeSH terms
- Administration, Intranasal, Animals, Brain, Female, Cyclosporine, Rats, Sprague-Dawley, Rats, Tandem Mass Spectrometry, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.